595024 Disclosed herein is a compound which is NN-dimethyl-5-(2-methyl-6-((5-methylpyrazin-2-yl)carbomoyl-4-yloxy)pyrimidine-2-carboxamide a pharmaceutical composition comprising it and a pharmaceutical composition further comprising an anti-obesity agent and an anti-diabetic agent. Wherein said anti-obesity agent is selected from the group consisting of dirlotapide mitratapide implitapide lorcaserin cetilistat PYY3-36 naltrexone oleoyl-estrone obinepitide pramlintide tesofensine leptin liraglut...

PURPOSE: A pharmaceutical composition containing alpha-glucosidaase inhibitors and beer yeast is provided to lower blood glucose after eating a meal and to enhance insulin in blood. CONSTITUTION: A pharmaceutical composition for preventing or treating diabetes contains alpha-glucosidase inhibitors and beer yeast as active ingredients. The alpha-glucosidase inhibitor is acarbose voglibose and miglitol soybean fermentation soybean fermented extract pine needle distiller concentrate guava leaf extr...

Disclosed herein are compositions comprising 1) 4-[3-amino-4(2,4,5-trifluorophenyl)butanoyl]-3-piperazin-2-one derivatives of formula I, wherein X is OR1, SR1, or NR1R2, and the other substituents are as defined within the specification, and 2) one or more other antidiabetic or antiobesity agents, such as alpha-glucosidase inhibitors selected from acarbose, voglibose, emiglitate and miglitol. Said compositions are useful for the prevention and treatment of diabetes or obesity.

COMPOSIÇÕES FARMACEUTICAS COMPREENDENDO SUBSTANCIAS ANTIDIABETES COMBINADAS PARA USO EM DIABETES MELLITUSA presente invenção está relacionada com a indústria farmacêutica em geral e com a indústriafarmacêutica produtora de medicamentos para o controle de diabetes em particular. Mais especificamente se trata de uma composição formada por substâncias anti-diabéticas de diferentes tipos em combinação. A composição se caracteriza em que tal combinação ou associação consiste em duas ou três substânci...

Reivindicacion 1: Una composicion farmacéutica caracterizada porque comprende: (a) un inhibidor de SGLT2 y (b) un inhibidor de DPPIV y (c) un tercer agente antidiabético seleccionado entre el grupo G3 que consiste en biguanidas tiazolidindionas sulfonilureas glinidas inhibidores de la alfa-glucosidasa análogos de GLP-1 o una sal farmacéuticamente aceptable de los mismos. Reivindicacion 2: La composicion farmacéutica de acuerdo con la reivindicacion 1 caracterizada porque el inhibidor de SGLT2 se...